Eventide Asset Management KROS Position
Exited4-Fund ConvergenceEventide Asset Management exited their position in Keros Therapeutics Inc. (KROS) in Q1 2025, after holding the stock for 9 quarters.
The position was first reported in Q1 2023 and has been tracked across 9 quarterly 13F filings.
KROS is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 39.6% of float with 4.5 days to cover, indicating significant bearish positioning against the stock.
About Keros Therapeutics Inc.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Full company profile →Short Interest
39.6%
4.5 days to cover
Eventide Asset Management KROS Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q1 2025 | Exited | 0 | -380,000 | $0 |
| Q4 2024 | Held | 380,000 | — | $6.0M |
| Q3 2024 | Decreased | 380,000 | -119,208 | $22.1M |
| Q2 2024 | Decreased | 499,208 | -180,792 | $22.8M |
| Q1 2024 | Increased | 680,000 | +100,000 | $45.0M |
| Q4 2023 | Held | 580,000 | — | $23.1M |
| Q3 2023 | Held | 580,000 | — | $18.5M |
| Q2 2023 | Increased | 580,000 | +280,000 | $23.3M |
| Q1 2023 | New | 300,000 | +300,000 | $12.8M |
Frequently Asked Questions
Does Eventide Asset Management own KROS?
No. Eventide Asset Management exited their position in Keros Therapeutics Inc. (KROS) in Q1 2025. They previously held the stock for 9 quarters.
How many hedge funds own KROS?
4 specialist biotech hedge funds currently hold KROS, including OrbiMed Advisors, Redmile Group, Tang Capital Management and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Eventide Asset Management first buy KROS?
Eventide Asset Management's position in KROS was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Eventide Asset Management's KROS position increasing or decreasing?
Eventide Asset Management completely exited their KROS position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
KROSCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Eventide Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →